ONCOMATRYX raises €25 Million to foster OMTX705 Clinical Trials

ONCOMATRYX raises €25 Million to foster OMTX705 Clinical Trials – Oncomatryx Skip to content ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-in-class ADC targeting FAP. The funding round was led by the company’s existing investors and included a €10 million strategic investment from Centro para el Desarrollo Tecnologico e Innovacion (CDTI). This endorsement highlights the confidence in ONCOMATRYX pioneering ADCs to treat metastatic solid tumors. “We are thrilled to count on the continued support of our existing investors and welcome CDTI through its Innvierte Estrategico program,” said Dr. Laureano Simon, CEO of ONCOMATRYX. “This funding validates our clinical progress and equips us to execute on critical milestones and deliver transformative therapies to patients.” Phase I clinical results of OMTX705, a novel ADC targeting Fibroblast Activation Protein in the Cancer-Associated Fibroblasts, will be presented at major Oncology conferences along 2025. Manage Consent To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions. Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage consent

The release as fetched from its publisher. oncomatryx.com ↗